App1. No. 10/576,402

REMARKS

Examiner Samala called the undersigned on October 5, 2007 and said that in claim 1, 4 and 7, it could not be determined if the two compounds were being employed together or individually.

Examiner Samala said that from the specification, it appears that it was intended to claim the individual employment of the two compounds.

Examiner Samala called the undersigned on October 9, 2007 and said that if claims 1 to 3 were canceled, he may allow the method of treatment claims.

Claim 4 was amended hereinabove to recite a Markush group of the two compounds (or pharmaceutically acceptable salts thereof). Support for the amendment to claim 4 is found in the specification on page 8, last paragraph; the paragraph bridging pages 4 and 5 ("pharmaceutically acceptable salts") and the last full paragraph on page 6 ("carriers").

Editorial revisions were made to claims 5 and 6.

New claims 10 and 11 recite the individual compounds recited in claims 1 and 4.

Appl. No. 10/576,402

Entry of the above amendments is respectfully requested.

An INFORMATION DISCLOSURE STATEMENT is being filed concomitantly herewith. By Express Mail, on even date herewith, a SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT is being filed to submit a full copy of JP 9-295970.

If the Examiner has any comments, questions, objections or recommendations, the Examiner is invited to telephone the undersigned at the telephone number given below for prompt action.

Respectfully submitted,

Frishauf, Holtz, Goodman & Chick, P.C. 220 Fifth Avenue, 16th Fl. New York, NY 10001-7708 Tel. Nos. (212) 319-4900 (212) 319-4551/Ext. 219 Fax No.: (212) 319-5101

Richard S. Barth Req. No. 28,180

E-Mail Address: BARTH@FHGC-LAW.COM

Enc.: INFORMATION DISCLOSURE STATEMENT